Companion Diagnostics Market Research Report - Forecast till 2027

Companion Diagnostics Market: Information By Products & Services (Assays, Kits & Reagents, Software & Services), Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH) and Immunohistochemistry (IHC)), Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases), End-User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations and Laboratories) - Forecast till 2027

ID: MRFR/MED/2231-CR | May, 2020 | Region : Global

Companion Diagnostics Market Overview


According to MRFR, the Companion Diagnostics Market is poised to register a CAGR of 20.29% to reach USD 8.08 Billion by 2027. The rising need for sequencing of the next decade, the increasing importance of companion diagnostics in drug production, and the growing number of clinical trials are the significant factors driving the growth of companion diagnostics market.


COVID-19 Analysis


The lockdown and social distancing controls imposed in these COVID-19 countries had a negative effect on the supply chain of these goods.


Market Dynamics


Drivers


Increasing Prevalence of Chronic Diseases Fuels the Market Growth


over the forecast period, the companion diagnostics market is projected to experience substantial growth due to a rise in R&D of targeted therapies, an increase in demand for customised medicine with increased recognition in developing markets, the development of new biomarkers for various diseases, and a higher number of unmet cancer care needs. It is expected that the growing preference for customised medicine, expanded cooperation between businesses and co-development of drug diagnostics would fuel companion diagnostics market growth. The development of the global companion diagnostics industry is motivated by the advantages of companion diagnostics, the growing demand for tailored treatment, the rising global cancer prevalence, and the ever-increasing application fields of companion diagnostics.


Opportunities


Expanding Regulatory Framework  Creates Growth Avenues for Key Players


It is also expected that the growing number of product approvals from global players would fuel demand growth. In the early stages of drug growth, pharmaceutical and biopharmaceutical firms are actively striving to incorporate patient-selection diagnostic frameworks and provide the best applicant for targeted therapies. The development of the companion diagnostics industry is further supported by this. Compared to other sequencing methods, next-generation sequencing discovers several biomarkers for multiple drug treatments in a shorter time span. The use of NGS panels in one test to assess biomarkers has the potential to help treat several different forms of cancers.


Restraints


High Costs of Companion Diagnostics to Impede Market Growth


Despite having guaranteed returns on investment, the high initial cost keeps these tests out of the reach of a large portion of end users, especially those in developed countries. This allows end-users, such as pharmaceutical firms, reference labs, hospitals, and CROs, who see the use of such diagnostic testing as a burden on their budgets, to opt for diagnostic services from third parties.


Segmental Analysis


Global Companion Diagnostics Market has been segmented by Technology, Indication, Products & Services, and End Users.


By-Products & Services


The companion diagnostics market, based on products & services, has been bifurcated into kits, & reagents, assays, and software & services. Growing demand for kits and reagents during the COVID 19 pandemic is likely to lead the companion diagnostics market.


By Technology


The companion diagnostics market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in-situ hybridization, immunohistochemistry, and other developments has been bifurcated on the basis of technology. The ease of use and widespread availability of PCR kits & reagents in companion diagnostic research pushes the PCR segment with increasing PCR applications.


By Indication


The indication-based industry has been categorised into cancer, neurological disorders, respiratory diseases, infectious diseases, and others. The cancer market is currently the main revenue generation segment and is expected to rise substantially over the forecast period. 


By End-User


The companion diagnostics industry has been categorised into pharmaceutical & biopharmaceutical firms, hospitals, contract testing organisations, and those focused on end-users. Due to their growing popularity in drug production and the increasing significance of companion diagnostic biomarkers, the large share of the pharma and biopharmaceutical segment can primarily be attributed to the widespread use of companion diagnostics in these sectors.


Regional Analysis


Global Companion Diagnostics Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Americas to Lead with Superior Healthcare Facilities


The field of the Americas is likely to lead the global companion diagnostics market. The high incidence rate of cancer and other chronic diseases and increasing healthcare spending in the area can be due to this. In addition, market development is also projected to drive the rising number of healthcare organisations working on generated genomic databases to understand the human genome and growing research activities in this area using companion diagnostic kits.


Presence of Major Players to Lead European Market


During the review period, the European market for companion diagnostics is expected to be the second-highest. The growth of the regional industry is projected to fuel the participation of a significant number of companies and increasing research and development activities to improve personalised drug treatment for cancer patients. In addition, increasing per capita income raises the preference for personalised treatment, further fuelling consumer growth.


APAC to Witness the Fastest Growth


Due to the extreme increasing number of patients with cancer, cardiovascular and neurological disorders, Asia-Pacific is expected to be the fastest growing region. Moreover, business development is also positively influenced by the growing incidence of infectious diseases. The growth of the APAC companion diagnostics market is projected to be driven by the high occurrence of cancer, increasing proteomics & genomics research, rising research funding, increasing investments by pharmaceutical and biotechnology firms, and increasing awareness of customised therapeutics in many APAC countries.


MEA to witness Gradual Growth


Due to rising cancer cases and increasing tastes for customised drugs, the Middle East & Africa market is expected to experience steady growth. Thanks to the rising number of hospitals, research labs, increasing investment by healthcare firms, a growing number of cancer cases, and increasing drug discovery, the Middle East & Africa market is expected to experience steady growth.


Competitive Landscape


Growing R&D Projects to Boost Market Growth


Acquisitions, alliances, growth, and product releases were some of the main tactics adopted by players operating in the global companion diagnostics industry.


June 2020: A strategic collaboration was formed between Thermo Fisher Science Inc. and Agios Pharmaceuticals to co-develop a second companion oncology diagnostic tool.



  • Hoffmann-La Roche Ltd (Switzerland)

  • Thermo Fisher Scientific Inc. (US)

  • Agilent Technologies, Inc. (US)

  • QIAGEN (Germany)

  • Abbott (US)

  • bioMérieux SA (France)

  • Leica Biosystems Nussloch GmbH (Germany)

  • Illumina, Inc. (US)

  • Myriad Genetics, Inc. (US)

  • ArcherDX, Inc. (US)

  • Foundation Medicine, Inc. (US)

  • NG Biotech (France)

  • ICON plc (Ireland)

  • Invivoscribe, Inc. (US)

  • Abnova Corporation (Taiwan)

  • Guardant Health (US)


Recent Development


December 2020: HalioDx SAS, the leading immuno-oncology testing firm for cancer immunological diagnosis, announced that it reached an exclusive distribution deal in Brazil with Diagnosticos da America (DASA) SA for the commercialization of Immunoscore.


September 2020: Roche introduced a highly effective SARS-CoV-2 antibody test that provided fast results. The introduction of such highly productive tests encouraged the development of the business to some degree during the Covid-19 pandemic.


September 2020: Sysmex Corporation introduced the Covid-19 virus antigen detection reagent. The implementation of such superior quality reagents had a positive effect on the revenue production of the business.


Report Overview


By-Products & Services



  • Assays, Kits, & Reagents

  • Software & Services


By Technology



  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • In Situ Hybridization (ISH)

  • Immunohistochemistry (IHC)

  • Others


By Indication



  • Cancer

  • Neurological Diseases

  • Infectious Diseases

  • Cardiovascular Diseases

  • Others


By End-User



  • Pharmaceutical & Biopharmaceutical Companies

  • Contract Research Organizations

  • Laboratories

  • Others

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 18

1.1.1 MARKET SYNOPSIS 18

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 19

2.2 RESEARCH OBJECTIVE 19

2.3 LIST OF ASSUMPTIONS 19

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 21

3.2 DATA MINING 21

3.3 SECONDARY RESEARCH 22

3.4 PRIMARY RESEARCH 23

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 25

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26

3.6.1 BOTTOM-UP APPROACH 26

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 27

3.8 VALIDATION 27

4 MARKET DYNAMICS

4.1 OVERVIEW 28

4.2 DRIVERS 29

4.2.1 RISING PREFERENCE OF PERSONALIZED MEDICINE 29

4.2.2 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT 29

4.2.3 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS 29

4.3 RESTRAINTS 31

4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS 31

4.3.2 LIMITED ADOPTION OF CDX AND PRESENCE OF ALTERNATIVE THERAPIES 31

4.4 OPPORTUNITIES 32

4.4.1 EXPANSION INTO NEWER INDICATION AREAS 32

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 33

5.1.1 THREAT OF NEW ENTRANTS 33

5.1.2 BARGAINING POWER OF SUPPLIERS 34

5.1.3 THREAT OF SUBSTITUTES 34

5.1.4 BARGAINING POWER OF BUYERS 34

5.1.5 INTENSITY OF RIVALRY 34

5.2 SUPPLY CHAIN ANALYSIS 35

5.2.1 R&D AND DESIGNING 36

5.2.2 MANUFACTURING 36

5.2.3 DISTRIBUTION 36

5.2.4 MARKETING & SALES 36

5.2.5 POST-SALES MONITORING 36

5.3 IMPACT OF CORONAVIRUS (COVID)-19 36

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

6.1 OVERVIEW 37

6.2 ASSAYS, KITS, & REAGENTS 38

6.3 SOFTWARE & SERVICES 38

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.1 OVERVIEW 40

7.2 POLYMERASE CHAIN REACTION (PCR) 41

7.3 NEXT-GENERATION SEQUENCING (NGS) 42

7.4 IN SITU HYBRIDIZATION (ISH) 42

7.5 IMMUNOHISTOCHEMISTRY (IHC) 43

7.6 OTHERS 43

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION

8.1 OVERVIEW 44

8.2 CANCER 45

8.2.1 LUNG CANCER 46

8.2.2 BREAST CANCER 46

8.2.3 COLORECTAL CANCER 47

8.2.4 GASTRIC CANCER 47

8.2.5 MELANOMA 48

8.2.6 OTHERS 48

8.3 NEUROLOGICAL DISEASES 48

8.4 INFECTIOUS DISEASES 49

8.5 CARDIOVASCULAR DISEASES 50

8.6 OTHERS 50

9 COMPANION DIAGNOSTICS MARKET, BY END USER

9.1 OVERVIEW 51

9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 52

9.3 CONTRACT RESEARCH ORGANIZATIONS 52

9.4 LABORATORIES 53

9.5 OTHERS 54

10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION

10.1 OVERVIEW 55

10.2 AMERICAS 57

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.2.1 NORTH AMERICA 59

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.2.1.1 US 61

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.2.1.2 CANADA 63

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.2.2 LATIN AMERICA 65

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3 EUROPE 68

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1 WESTERN EUROPE 71

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.1 GERMANY 73

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.2 FRANCE 75

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.3 UK 77

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.4 ITALY 78

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.5 SPAIN 80

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.1.6 REST OF WESTERN EUROPE 82

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.3.2 EASTERN EUROPE 85

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4 ASIA-PACIFIC 87

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.1 CHINA 89

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.2 JAPAN 91

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.3 INDIA 93

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.4 AUSTRALIA 95

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.5 SOUTH KOREA 98

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.4.6 REST OF ASIA-PACIFIC 99

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.5 MIDDLE EAST & AFRICA 102

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.5.1 MIDDLE EAST 104

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

10.5.2 AFRICA 106

COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

COMPANION DIAGNOSTICS MARKET, BY INDICATION

COMPANION DIAGNOSTICS MARKET, BY END USER

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 109

11.2 MARKET SHARE ANALYSIS 109

11.3 COMPETITOR DASHBOARD 110

11.4 COMPETITIVE BENCHMARKING 111

11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPANION DIAGNOSTICS MARKET 112

11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 113

11.7 KEY DEVELOPMENTS AND GROWTH STRATEGIES 114

11.7.1 MERGERS 114

11.7.2 EXPANSIONS 114

11.7.3 ACQUISITIONS 115

11.7.4 AGREEMENTS/COLLABORATIONS/PARTNERSHIPS 115

11.7.5 PRODUCT APPROVALS/LAUNCHES 118

11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 121

11.8.1 SALES 121

11.8.2 R&D EXPENDITURE 121

12 COMPANY PROFILES

12.1 F. HOFFMANN-LA ROCHE LTD 122

12.1.1 COMPANY OVERVIEW 122

12.1.2 FINANCIAL OVERVIEW 123

12.1.3 PRODUCTS/SERVICES OFFERED 123

12.1.4 KEY DEVELOPMENTS 124

12.1.5 SWOT ANALYSIS 124

12.1.6 KEY STRATEGIES 125

12.2 THERMO FISHER SCIENTIFIC INC. 126

12.2.1 COMPANY OVERVIEW 126

12.2.2 FINANCIAL OVERVIEW 126

12.2.3 PRODUCTS/SERVICES OFFERED 127

12.2.4 KEY DEVELOPMENTS 127

12.2.5 SWOT ANALYSIS 128

12.2.6 KEY STRATEGIES 128

12.3 AGILENT TECHNOLOGIES, INC. 129

12.3.1 COMPANY OVERVIEW 129

12.3.2 FINANCIAL OVERVIEW 129

12.3.3 PRODUCTS/SERVICES OFFERED 130

12.3.4 KEY DEVELOPMENTS 130

12.3.5 SWOT ANALYSIS 131

12.3.6 KEY STRATEGIES 131

12.4 QIAGEN 132

12.4.1 COMPANY OVERVIEW 132

12.4.2 FINANCIAL OVERVIEW 132

12.4.3 PRODUCTS/SERVICES OFFERED 133

12.4.4 KEY DEVELOPMENTS 133

12.4.5 SWOT ANALYSIS 134

12.4.6 KEY STRATEGIES 134

12.5 ABBOTT 135

12.5.1 COMPANY OVERVIEW 135

12.5.2 FINANCIAL OVERVIEW 135

12.5.3 PRODUCTS/SERVICES OFFERED 136

12.5.4 KEY DEVELOPMENTS 136

12.5.5 SWOT ANALYSIS 137

12.5.6 KEY STRATEGIES 137

12.6 BIOMÉRIEUX SA 138

12.6.1 COMPANY OVERVIEW 138

12.6.2 FINANCIAL OVERVIEW 138

12.6.3 PRODUCTS/SERVICES OFFERED 139

12.6.4 KEY DEVELOPMENTS 139

12.6.5 SWOT ANALYSIS 139

12.6.6 KEY STRATEGIES 139

12.7 LEICA BIOSYSTEMS NUSSLOCH GMBH 140

12.7.1 COMPANY OVERVIEW 140

12.7.2 FINANCIAL OVERVIEW 140

12.7.3 PRODUCTS/SERVICES OFFERED 141

12.7.4 KEY DEVELOPMENTS 141

12.7.5 SWOT ANALYSIS 141

12.7.6 KEY STRATEGIES 142

12.8 ILLUMINA, INC. 143

12.8.1 COMPANY OVERVIEW 143

12.8.2 FINANCIAL OVERVIEW 143

12.8.3 PRODUCTS/SERVICES OFFERED 144

12.8.4 KEY DEVELOPMENTS 144

12.8.5 SWOT ANALYSIS 145

12.8.6 KEY STRATEGIES 145

12.9 MYRIAD GENETICS, INC. 146

12.9.1 COMPANY OVERVIEW 146

12.9.2 FINANCIAL OVERVIEW 146

12.9.3 PRODUCTS/SERVICES OFFERED 147

12.9.4 KEY DEVELOPMENTS 147

12.9.5 SWOT ANALYSIS 148

12.9.6 KEY STRATEGIES 148

12.10 ARCHERDX, INC. 149

12.10.1 COMPANY OVERVIEW 149

12.10.2 FINANCIAL OVERVIEW 149

12.10.3 PRODUCTS/SERVICES OFFERED 149

12.10.4 KEY DEVELOPMENTS 150

12.10.5 SWOT ANALYSIS 150

12.10.6 KEY STRATEGIES 151

12.11 FOUNDATION MEDICINE, INC. 152

12.11.1 COMPANY OVERVIEW 152

12.11.2 FINANCIAL OVERVIEW 152

12.11.3 PRODUCTS/SERVICES OFFERED 152

12.11.4 KEY DEVELOPMENTS 152

12.11.5 SWOT ANALYSIS 154

12.11.6 KEY STRATEGIES 154

12.12 NG BIOTECH 155

12.12.1 COMPANY OVERVIEW 155

12.12.2 FINANCIAL OVERVIEW 155

12.12.3 PRODUCTS/SERVICES OFFERED 155

12.12.4 KEY DEVELOPMENTS 155

12.12.5 SWOT ANALYSIS 156

12.12.6 KEY STRATEGIES 156

12.13 ICON PLC 157

12.13.1 COMPANY OVERVIEW 157

12.13.2 FINANCIAL OVERVIEW 157

12.13.3 PRODUCTS/SERVICES OFFERED 158

12.13.4 KEY DEVELOPMENTS 158

12.13.5 SWOT ANALYSIS 159

12.13.6 KEY STRATEGIES 159

12.14 INVIVOSCRIBE, INC. 160

12.14.1 COMPANY OVERVIEW 160

12.14.2 FINANCIAL OVERVIEW 160

12.14.3 PRODUCTS/SERVICES OFFERED 160

12.14.4 KEY DEVELOPMENTS 160

12.14.5 SWOT ANALYSIS 161

12.14.6 KEY STRATEGIES 161

12.15 ABNOVA CORPORATION 162

12.15.1 COMPANY OVERVIEW 162

12.15.2 FINANCIAL OVERVIEW 162

12.15.3 PRODUCTS/SERVICES OFFERED 162

12.15.4 KEY DEVELOPMENTS 162

12.15.5 SWOT ANALYSIS 163

12.15.6 KEY STRATEGIES 163

12.16 GUARDANT HEALTH 164

12.16.1 COMPANY OVERVIEW 164

12.16.2 FINANCIAL OVERVIEW 164

12.16.3 PRODUCTS/SERVICES OFFERED 165

12.16.4 KEY DEVELOPMENTS 165

12.16.5 SWOT ANALYSIS 165

12.16.6 KEY STRATEGIES 166

13 APPENDIX

13.1 REFERENCES 167

13.2 RELATED REPORTS 168

14 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 19

TABLE 2 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020-2027 (USD MILLION) 37

TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR ASSAYS, KITS, & REAGENTS, BY REGION, 2020-2027 (USD MILLION) 38

TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR SOFTWARE & SERVICES, BY REGION, 2020-2027 (USD MILLION) 39

TABLE 5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 41

TABLE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2020-2027 (USD MILLION) 41

TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2020-2027 (USD MILLION) 42

TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IN SITU HYBRIDIZATION (ISH), BY REGION, 2020-2027 (USD MILLION) 42

TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2020-2027 (USD MILLION) 43

TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION) 43

TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020-2027 (USD MILLION) 44

TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY TYPE, 2020-2027 (USD MILLION) 45

TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY REGION, 2020-2027 (USD MILLION) 45

TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LUNG CANCER, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR BREAST CANCER, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR COLORECTAL CANCER, BY REGION, 2020-2027 (USD MILLION) 47

TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR GASTRIC CANCER, BY REGION, 2020-2027 (USD MILLION) 47

TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR MELANOMA, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER CANCERS, BY REGION, 2020-2027 (USD MILLION) 48

TABLE 20 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2020-2027 (USD MILLION) 49

TABLE 21 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION) 49

TABLE 22 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION) 50

TABLE 23 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER DISEASES, BY REGION, 2020-2027 (USD MILLION) 50

TABLE 24 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION) 51

TABLE 25 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION) 52

TABLE 26 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 53

TABLE 27 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 53

TABLE 28 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION) 54

TABLE 29 GLOBAL: COMPANION DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 30 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 31 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 58

TABLE 32 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 58

TABLE 33 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 58

TABLE 34 AMERICAS: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 35 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 36 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

TABLE 37 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 60

TABLE 38 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 60

TABLE 39 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 60

TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 41 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 42 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 61

TABLE 43 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 62

TABLE 44 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 62

TABLE 45 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 46 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 47 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 63

TABLE 48 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 64

TABLE 49 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 64

TABLE 50 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 51 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 65

TABLE 53 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 66

TABLE 54 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 66

TABLE 55 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 56 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 57 EUROPE: COMPANION DIAGNOSTICS MARKET, BY REGION, 2020-2027 (USD MILLION) 68

TABLE 58 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 69

TABLE 59 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 69

TABLE 60 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 69

TABLE 61 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 63 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 71

TABLE 64 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 71

TABLE 65 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71

TABLE 66 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 72

TABLE 67 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 68 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 69 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 73

TABLE 70 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73

TABLE 71 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 74

TABLE 72 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 73 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 74 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 75

TABLE 75 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75

TABLE 76 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 75

TABLE 77 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 78 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 76

TABLE 79 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 77

TABLE 80 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 77

TABLE 81 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 77

TABLE 82 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 83 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 84 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 78

TABLE 85 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 79

TABLE 86 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 79

TABLE 87 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 88 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 89 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 80

TABLE 90 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 81

TABLE 91 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 81

TABLE 92 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 93 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 94 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 82

TABLE 95 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83

TABLE 96 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 83

TABLE 97 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 98 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 84

TABLE 99 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 85

TABLE 100 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 85

TABLE 101 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 85

TABLE 102 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 103 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 104 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87

TABLE 105 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 88

TABLE 106 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88

TABLE 107 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 88

TABLE 108 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 109 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 110 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 89

TABLE 111 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 90

TABLE 112 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 90

TABLE 113 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 114 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 115 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 91

TABLE 116 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 92

TABLE 117 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 92

TABLE 118 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 119 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 93

TABLE 120 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 93

TABLE 121 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 94

TABLE 122 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 94

TABLE 123 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 124 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 125 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 95

TABLE 126 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 96

TABLE 127 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 96

TABLE 128 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 129 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 97

TABLE 130 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 98

TABLE 131 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 98

TABLE 132 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 98

TABLE 133 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 134 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 135 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 99

TABLE 136 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 100

TABLE 137 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 100

TABLE 138 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 139 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 101

TABLE 140 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 102

TABLE 141 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 102

TABLE 142 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 103

TABLE 143 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 103

TABLE 144 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 145 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 104

TABLE 146 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 104

TABLE 147 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 105

TABLE 148 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 105

TABLE 149 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 150 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 151 AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 106

TABLE 152 AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 107

TABLE 153 AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 107

TABLE 154 AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 155 AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 108

TABLE 156 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET 113

TABLE 157 MERGERS: GLOBAL COMPANION DIAGNOSTICS MARKET 114

TABLE 158 EXPANSIONS:GLOBAL COMPANION DIAGNOSTICS MARKET 114

TABLE 159 ACQUISITIONS: GLOBAL COMPANION DIAGNOSTICS MARKET 115

TABLE 160 AGREEMENTS/COLLABORATIONS/PARTNERSHIPS: GLOBAL COMPANION DIAGNOSTICS MARKET 115

TABLE 161 PRODUCT APPROVALS/LAUNCHES: GLOBAL COMPANION DIAGNOSTICS MARKET 118

TABLE 162 MAJOR PLAYERS R&D EXPENDITURE, 2018 121

TABLE 163 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 123

TABLE 164 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 124

TABLE 165 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 127

TABLE 166 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 127

TABLE 167 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 130

TABLE 168 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS 130

TABLE 169 QIAGEN: PRODUCTS/SERVICES OFFERED 133

TABLE 170 QIAGEN: KEY DEVELOPMENTS 133

TABLE 171 ABBOTT: PRODUCTS/SERVICES OFFERED 136

TABLE 172 ABBOTT: KEY DEVELOPMENTS 136

TABLE 173 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 139

TABLE 174 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS/SERVICES OFFERED 141

TABLE 175 LEICA BIOSYSTEMS NUSSLOCH GMBH: KEY DEVELOPMENTS 141

TABLE 176 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 144

TABLE 177 ILLUMINA, INC.: KEY DEVELOPMENTS 144

TABLE 178 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES OFFERED 147

TABLE 179 MYRIAD GENETICS, INC.: KEY DEVELOPMENTS 147

TABLE 180 ARCHERDX, INC.: PRODUCTS/SERVICES OFFERED 149

TABLE 181 ARCHERDX, INC.: KEY DEVELOPMENTS 150

TABLE 182 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES OFFERED 152

TABLE 183 FOUNDATION MEDICINE, INC.: KEY DEVELOPMENTS 152

TABLE 184 NG BIOTECH: PRODUCTS/SERVICES OFFERED 155

TABLE 185 ICON PLC: PRODUCTS/SERVICES OFFERED 158

TABLE 186 INVIVOSCRIBE, INC.: PRODUCTS/SERVICES OFFERED 160

TABLE 187 INVIVOSCRIBE, INC.: KEY DEVELOPMENTS 160

TABLE 188 ABNOVA CORPORATION: PRODUCTS/SERVICES OFFERED 162

TABLE 189 GUARDANT HEALTH: PRODUCTS/SERVICES OFFERED 165

TABLE 190 GUARDANT HEALTH: KEY DEVELOPMENTS 165

15 LIST OF FIGURES

FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET STRUCTURE 20

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 26

FIGURE 3 MARKET DYNAMICS: GLOBAL COMPANION DIAGNOSTICS MARKET 28

FIGURE 4 DRIVERS: IMPACT ANALYSIS 30

FIGURE 5 RESTRAINTS: IMPACT ANALYSIS 31

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET 33

FIGURE 7 SUPPLY CHAIN ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET 35

FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020 & 2027 (USD MILLION) 37

FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 & 2027 (USD MILLION) 40

FIGURE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020 & 2027 (USD MILLION) 44

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2020 & 2027 (USD MILLION) 51

FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 & 2027 (USD MILLION) 55

FIGURE 13 AMERICAS: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 57

FIGURE 14 EUROPE: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 68

FIGURE 15 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET SHARE, BY COUNTRY, 2020 (%) 87

FIGURE 16 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 102

FIGURE 17 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, 2020 (%) 109

FIGURE 18 COMPETITOR DASHBOARD: GLOBAL COMPANION DIAGNOSTICS MARKET 110

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS 111

FIGURE 21 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL COMPANION DIAGNOSTICS MARKET 112

FIGURE 22 COMPANION DIAGNOSTICS MARKET, COMPETITIVE LANDSCAPE (% SHARE) 114

FIGURE 23 SALES, 2018 121

FIGURE 24 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 123

FIGURE 25 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 124

FIGURE 26 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 126

FIGURE 27 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 128

FIGURE 28 AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 129

FIGURE 29 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS 131

FIGURE 30 QIAGEN: FINANCIAL OVERVIEW 132

FIGURE 31 QIAGEN: SWOT ANALYSIS 134

FIGURE 32 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 135

FIGURE 33 ABBOTT: SWOT ANALYSIS 137

FIGURE 34 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 138

FIGURE 35 BIOMÉRIEUX SA: SWOT ANALYSIS 139

FIGURE 36 LEICA BIOSYSTEMS NUSSLOCH GMBH: FINANCIAL OVERVIEW SNAPSHOT 140

FIGURE 37 LEICA BIOSYSTEMS NUSSLOCH GMBH: SWOT ANALYSIS 141

FIGURE 38 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT 143

FIGURE 39 ILLUMINA, INC.: SWOT ANALYSIS 145

FIGURE 40 MYRIAD GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT 146

FIGURE 41 MYRIAD GENETICS, INC.: SWOT ANALYSIS 148

FIGURE 42 ARCHERDX, INC.: SWOT ANALYSIS 150

FIGURE 43 FOUNDATION MEDICINE, INC.: SWOT ANALYSIS 154

FIGURE 44 NG BIOTECH: SWOT ANALYSIS 156

FIGURE 45 ICON PLC: FINANCIAL OVERVIEW SNAPSHOT 157

FIGURE 46 ICON PLC: SWOT ANALYSIS 159

FIGURE 47 INVIVOSCRIBE, INC.: SWOT ANALYSIS 161

FIGURE 48 ABNOVA CORPORATION: SWOT ANALYSIS 163

FIGURE 49 GUARDANT HEALTH: FINANCIAL OVERVIEW SNAPSHOT 164

FIGURE 50 GUARDANT HEALTH: SWOT ANALYSIS 165

Companion Diagnostic Market